Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.47 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.45 |
| ▸ | TFPI | P10646 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275450 | 0.93 | CXCR4 (0.46) | APLNRCXCR4 | |
| SCHEMBL28356821 | 0.89 | CXCR4 (0.47) | APLNROPRM1CXCR4 | |
| SCHEMBL29374733 | 0.88 | CXCR4 (0.45) | APLNRCXCR4 | |
| SCHEMBL31655163 | 0.87 | CXCR4 (0.47) | APLNRCXCR4 | |
| SCHEMBL29628862 | 0.87 | IL23R (0.48) | APLNROPRM1OPRK1IL23RCXCR4 | |
| SCHEMBL24202254 | 0.86 | APLNR (0.46) | APLNROPRM1OPRK1IL23RCXCR4 | |
| SCHEMBL30887061 | 0.86 | CXCR4 (0.41) | OPRM1CXCR4 | |
| SCHEMBL29579268 | 0.85 | CXCR4 (0.48) | APLNROPRM1OPRK1CXCR4 | |
| SCHEMBL31655138 | 0.85 | NMUR2 (0.43) | OPRM1CXCR4 | |
| SCHEMBL30887066 | 0.84 | CXCR4 (0.45) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320251-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES | LISATA THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12351653-B1 | Pharmaceutical compositions comprising novel cyclic peptides | LISATA THERAPEUTICS, INC. | 2025-07-08 | — | — | US | disclosed |
| US-20250144169-A1 | iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | LISATA THERAPEUTICS INC (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4333897-A1 | IRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | Cend Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230201303-A1 | METHODS FOR TREATING PANCREATIC CANCER AND OTHER SOLID TUMORS | LISATA THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| CN-115867317-A | Methods for treating pancreatic cancer and other solid tumors | 澳大利亚药品中心私人有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4146274-A1 | METHODS FOR TREATING PANCREATIC CANCER AND OTHER SOLID TUMORS | Drugcendr Australia Pty Ltd. (AU) | 2023-03-15 | — | — | EP | disclosed |
| US-20230050515-A1 | iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | LISATA THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2022235852-A1 | IRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | CEND THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320251-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES | VIP, NGLY1, GRPR | APLNR 41/4885OPRM1 1959/4885OPRK1 1345/4885 |
| US-12351653-B1 | Pharmaceutical compositions comprising novel cyclic peptides | VIP, NGLY1, GRPR | APLNR 41/4885OPRM1 1959/4885OPRK1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.